Thyroid medication recalls
53 FDA-recorded recalls of thyroid medications, most recent Jul 2026 — newest first, straight from the FDA's own database.
Thyroid recalls are dominated by POTENCY, not contamination — tablets that assay below or above their labelled strength. That matters more here than for most drugs: levothyroxine is dosed in micrograms and titrated to a blood test, so a tablet that is subpotent under-treats hypothyroidism and one that is superpotent can push someone into hyperthyroid symptoms, and neither is visible in the pill. Recalls name specific lots and manufacturers. Do not stop thyroid medicine on your own — check your lot against the FDA notice and ask your pharmacist for a replacement, because interrupting it has its own consequences.
Levothyroxine Sodium Tablets
Class IISubpotent Drug
Major Pharmaceuticals · Jul 29, 2026
Levothyroxine Sodium Tablets
Class IISubpotent Drug
Major Pharmaceuticals · Jul 29, 2026
Levothyroxine Sodium Tablets
Class IISubpotent Drug
Major Pharmaceuticals · Jul 29, 2026
Levothyroxine Sodium Tablets
Class IISubpotent Drug
Major Pharmaceuticals · Jul 29, 2026
Levothyroxine Sodium Tablets
Class IISubpotent Drug
Major Pharmaceuticals · Jul 29, 2026
Levothyroxine Sodium Tablets
Class IISubpotent Drug
Major Pharmaceuticals · Jul 29, 2026
Levothyroxine Sodium Tablets
Class IISubpotent Drug
Major Pharmaceuticals · Jul 29, 2026
Levothyroxine Sodium Tablets
Class IISubpotent Drug
Major Pharmaceuticals · Jul 29, 2026
Levothyroxine Sodium Tablets
Class IISubpotent Drug
Major Pharmaceuticals · Jul 29, 2026
Levothyroxine Sodium Tablets
Class IISubpotent Drug
Major Pharmaceuticals · Jul 29, 2026
Levothyroxine Sodium Tablets
Class IISubpotent Drug
Major Pharmaceuticals · Jul 29, 2026
Levothyroxine Sodium Tablets
Class IISubpotent Drug
Major Pharmaceuticals · Jul 29, 2026
Levothyroxine Sodium Tablets
Class IISubpotent Drug
ACCORD HEALTHCARE, INC. · Jul 8, 2026
Levothyroxine Sodium Tablets USP 150 mcg
Class IISubpotent Drug
MACLEODS PHARMA USA, INC · Apr 1, 2026
Thyroid, USP, Rx only, Net Wt: 0.50kg, For Manufacturing, Processing or Repackag…
Class IISubpotent Drug
Specialty Process Labs LLC · Jan 28, 2026
Levothyroxine Sodium Tablets
Class IIProduct Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.
Alvogen, Inc · Jan 21, 2026
Levothyroxine Sodium Tablets
Class IISubpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range.
ACCORD HEALTHCARE, INC. · Oct 15, 2025
Levoxyl (levothyroxine sodium tablets
Class IISubpotent drug
Pfizer · Aug 20, 2025
Levothyroxine Sodium Tablets
Class IISubpotent Drug: Assay below the approved specification
ACCORD HEALTHCARE, INC. · Jul 23, 2025
Levothyroxine Sodium Tablets
Class IISubpotent Drug: Assay below the approved specification
ACCORD HEALTHCARE, INC. · Jul 23, 2025
Levothyroxine Sodium Tablets
Class IISubpotent Drug: Assay below the approved specification
ACCORD HEALTHCARE, INC. · Jul 23, 2025
Levothyroxine Sodium Tablets
Class IISubpotent Drug: Assay below the approved specification
ACCORD HEALTHCARE, INC. · Jul 23, 2025
Levothyroxine Sodium Tablets
Class IISubpotent Drug: Assay below the approved specification
ACCORD HEALTHCARE, INC. · Jul 23, 2025
Levothyroxine Sodium Tablets
Class IISubpotent Drug: Assay below the approved specification
ACCORD HEALTHCARE, INC. · Jul 23, 2025
Levothyroxine Sodium Tablets
Class IISubpotent Drug: Assay below the approved specification
ACCORD HEALTHCARE, INC. · Jul 23, 2025
Levothyroxine Sodium Tablets
Class IIIPresence of a foreign substance: black hair found embedded in tablet.
Macleods Pharmaceuticals Ltd · Jun 18, 2025
Levothyroxine Sodium Tablets
Class IISubpotent
ACCORD HEALTHCARE, INC. · May 7, 2025
Levothyroxine Sodium Tablets
Class IISubpotent
ACCORD HEALTHCARE, INC. · May 7, 2025
Levothyroxine Sodium Tablets
Class IISubpotent
ACCORD HEALTHCARE, INC. · May 7, 2025
Levothyroxine Sodium Tablets
Class IISubpotent
ACCORD HEALTHCARE, INC. · May 7, 2025
Levothyroxine Sodium Tablets
Class IISuper-Potent Drug: Out of specification potency results were obtained.
Mylan Institutional, Inc. · Mar 26, 2025
Levothyroxine Sodium Tablets
Class IISuper-Potent Drug: Out of specification potency results were obtained.
Mylan Institutional, Inc. · Mar 26, 2025
Levothyroxine Sodium Tablets
Class IIFailed Impurities/Degradation Specifications: Out of specifications result observed in the drug substance for impurity test during 3-month long term stability study.
Lupin Pharmaceuticals Inc. · Jan 8, 2025
Levothyroxine Sodium Tablets
Class IISubpotent and Superpotent Drug
Mylan Institutional, Inc. · Dec 18, 2024
Levothyroxine Sodium Tablets
Class IISubpotent and Superpotent Drug
Mylan Institutional, Inc. · Dec 18, 2024
Levothyroxine Sodium Tablets
Class IISubpotent and Superpotent Drug
Mylan Institutional, Inc. · Dec 18, 2024
Levothyroxine Sodium Tablets
Class IISubpotent and Superpotent Drug
Mylan Institutional, Inc. · Dec 18, 2024
Levothyroxine Sodium Tablets
Class IISubpotent and Superpotent Drug
Mylan Institutional, Inc. · Dec 18, 2024
Levothyroxine Sodium Tablets
Class IISubpotent and Superpotent Drug
Mylan Institutional, Inc. · Dec 18, 2024
Levothyroxine Sodium Tablets USP
Class IISuperpotent Drug and Subpotent Drug: potency failures obtained
Viatris Inc · Dec 18, 2024
Levothyroxine Sodium Tablets USP
Class IISuperpotent Drug and Subpotent Drug: potency failures obtained
Viatris Inc · Dec 18, 2024
Levothyroxine Sodium Tablets USP
Class IISuperpotent Drug and Subpotent Drug: potency failures obtained
Viatris Inc · Dec 18, 2024
Levothyroxine Sodium Tablets USP
Class IISuperpotent Drug and Subpotent Drug: potency failures obtained
Viatris Inc · Dec 18, 2024
Levothyroxine Sodium Tablets USP
Class IISuperpotent Drug and Subpotent Drug: potency failures obtained
Viatris Inc · Dec 18, 2024
Levothyroxine Sodium Tablets USP
Class IISuperpotent Drug and Subpotent Drug: potency failures obtained
Viatris Inc · Dec 18, 2024
Levothyroxine Sodium Tablets USP
Class IISuperpotent Drug and Subpotent Drug: potency failures obtained
Viatris Inc · Dec 18, 2024
Levothyroxine Sodium Tablets USP
Class IISuperpotent Drug and Subpotent Drug: potency failures obtained
Viatris Inc · Dec 18, 2024
Levothyroxine Sodium Tablets USP
Class IISuperpotent Drug and Subpotent Drug: potency failures obtained
Viatris Inc · Dec 18, 2024
Levothyroxine Sodium Tablets USP
Class IISuperpotent Drug and Subpotent Drug: potency failures obtained
Viatris Inc · Dec 18, 2024
Levothyroxine Sodium Tablets USP
Class IISuperpotent Drug and Subpotent Drug: potency failures obtained
Viatris Inc · Dec 18, 2024
Levothyroxine Sodium Tablets
Class IISubpotent drug
ACCORD HEALTHCARE, INC. · Dec 11, 2024
S.P.Labs, Thyroid, Full Strength, Rx only, For Manufacturing, Processing or Repa…
Class IIFailed Stability Specifications
Specialty Process Labs LLC · Apr 24, 2024
S.P Labs, Thyroid, USP, Rx only, For Manufacturing, Processing or Repackaging Us…
Class IIFailed Stability Specifications
Specialty Process Labs LLC · Apr 24, 2024
How to use this page
A drug appearing here does not mean your prescription is unsafe. Recalls name specific lots and manufacturers — open the recall to see the affected lot numbers, and match them against your bottle. Never stop a blood-pressure, cholesterol, diabetes, antidepressant or antibiotic medicine on your own because of a recall; confirm your lot, then ask your pharmacist for a replacement if it is affected.
Other categories: Blood pressure medication · Eye drop and ophthalmic · Cholesterol medication · Diabetes medication · Antidepressant · Antibiotic · Allergy and antihistamine · Hormonal and contraceptive · ADHD and stimulant medication · Opioid and pain medication · Seizure and epilepsy medication · Asthma and inhaler · Heartburn and acid-reflux medication. See also the full recalls tracker and the recall report.
Source: the openFDA drug Enforcement (recall) database. Recalls are matched to this category by the drug names in the FDA’s product description; a small number of category recalls may be missed if the description omits the ingredient. Figures are recall events, not units, and reflect our copy of the FDA data, refreshed daily. This is public regulatory data, not medical advice.